For Immediate Release: April 30, 2018
513-579-9911 x 12627
Medpace Receives First Place in ACRP-Avoca CRO Quality Awards
CINCINNATI, OH — (April 30, 2018) – Medpace (MEDP), a scientifically-driven, global full-service clinical research organization (CRO), was recognized with the first-ever ACRP-Avoca CRO Quality Award on April 27th during the ACRP-Avoca Awards and Recognition Ceremony taking place at the ACRP 2018 annual meeting. Medpace was announced as a finalist by ACRP in March.
About the Award
Finalists for the ACRP-Avoca Quality Awards were chosen by investigational sites through a research study conducted by The Avoca Group over an eight-week period in early 2018. In this research, investigational sites were asked to rate CRO attributes aligned to quality outcomes. Specifically, functional attributes that support quality into design, execution, and oversight of clinical trials, as well as soft-skill areas such as communication and partnership.
“We congratulate all the finalists for having proven their ability to work effectively with investigate sites. This includes their ability to appreciate site operations, manage relationships, and provide high-quality CRA support,” says Jim Kremidas, ACRP Executive Director. “Recognition of quality partners in the clinical trial community greatly supports our mission to promote excellence in clinical research.”
“We are thrilled to collaborate with ACRP and to give investigational sites a platform to recognize organizations who provide high-quality support in the clinical research process,” says Patricia Leuchten, CEO of The Avoca Group. “Continued collaboration between sites, sponsors, and CROs, will yield long-term, positive impact on the quality and execution of clinical trials.”
Congratulations to all of the Medpace colleagues who facilitate a culture of quality every day as we execute on our mission to accelerate the global development of safe and effective medical therapeutics.
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,500 people across 35 countries.